Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
J&J gene therapy fails ph. 3 rare eye disease trial
The treatment failed to improve the vision-guided mobility of patients with the eye disease X-linked retinitis pigmentosa.
Darren Incorvaia
May 5, 2025 11:33am
Immunic MS asset misses primary goal of midstage trial
Apr 30, 2025 3:05pm
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Apr 24, 2025 4:46am
Mural's IL-2 flop triggers 90% staff reduction
Apr 15, 2025 9:33am
Sanofi's hopes for $1.1B Kymab drug dented after ph. 2 asthma fail
Apr 15, 2025 7:34am
